A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.

by Sandra Gordon

New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.

by Laura Gesualdi-Gilmore

Findings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.

by Kyle Bagenstose

Adding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.

by Thomas Celona

The Cancer Today editors share the most impactful reporting on cancer research from 2024.

by Cancer Today staff

Our favorite Cancer Today stories from 2024, as picked by the editors.

Chest radiation may not be necessary for people with intermediate-risk breast cancer.

by Thomas Celona

Research finds certain people with low-risk DCIS may be able to forgo surgery or radiation.

by Thomas Celona

Most pancreatic ductal adenocarcinoma cases initially considered to be stage I are changed to a higher stage after surgery.

by Taneia Surles

Using high-dose testosterone after prostate cancer stops responding to androgen deprivation therapy can stop tumor growth.

by Sandra Gordon